AbbVie. has been granted a patent for a cryoprotectant designed to enhance the efficacy of a thermoelectric treatment device targeting subcutaneous lipid-rich cells. This non-freezing formulation prevents ice formation, allowing for effective cooling while preserving surrounding non-lipid-rich cells during treatment. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of July 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Cryoprotectant for treating subcutaneous lipid-rich cells
The patent US12070411B2 describes a system designed for the selective destruction of subcutaneous lipid-rich cells in a target region of a subject's skin. Central to this system is a thermoelectric treatment device that includes a fluid-cooled heat exchanger and a thermoelectric cooler. The device is engineered to lower the temperature of the target area for up to 30 minutes, effectively affecting lipid-rich cells while preserving adjacent non-lipid-rich cells. An absorbent, which can be a cotton pad or gauze, is positioned between the heat exchanging surface and the skin. This absorbent is preloaded with a cryoprotectant solution, primarily composed of 40% propylene glycol and 0.8% hydroxyethylcellulose, which is continuously supplied to the skin during the treatment period.
The claims further detail the operational parameters of the system, including the ability of the heat exchanging element to reach temperatures as low as -20°C. The cryoprotectant is designed to maintain a specific viscosity range and pH level, ensuring its effectiveness during the treatment. The absorbent's configuration allows it to cover the interface between the treatment device and the skin, facilitating optimal thermal coupling. The system's design aims to provide a targeted approach to lipid cell destruction while minimizing damage to surrounding tissues, highlighting its potential applications in cosmetic and medical treatments.
To know more about GlobalData’s detailed insights on AbbVie, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
